October 03, 2011 06:22 PM Eastern Daylight Time
The Law Firm of Weiss & Lurie Investigates Pharmaceutical Product Development, Inc.
NEW YORK--(BUSINESS WIRE)--Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Pharmaceutical Product Development, Inc. (NASDAQ: PPDI) (“PPDI”) arising from its proposed acquisition by affiliates of the Carlyle Group and Hellman & Friedman in an all cash transaction valued at approximately $3.9 billion. Under the terms of the transaction, PPDI shareholders will receive $33.25 per share.
Weiss & Lurie is investigating whether PPDI’s Board acted in the best interests of its shareholders in approving the transaction and whether the Board properly sought to maximize shareholder value. PPDI shares were trading above $33.00 as recently as August 2011, and several analysts have set price targets for PPDI above $33.25 with a high target price set at $38.00 per share.
If you own PPDI shares and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Joshua M. Rubin either by email at firstname.lastname@example.org or by telephone at (888) 593-4771.
Weiss & Lurie has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (such as insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading press releases or SEC filings), consumer fraud (such as false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at email@example.com or fill out the form on our website, http://www.weisslurie.com/contact/report_fraud/.
Attorney Advertising. Past results do not guarantee a similar outcome.
Tuesday, October 04, 2011
The Law Firm of Weiss & Lurie Investigates Pharmaceutical Product Development, Inc. | Business Wire